eClinical Technology and Industy News

Harvard Licenses Technology to Obatala Sciences to Advance Discovery in Obesity, Diabetes, and Cancer

Excerpt from the Press Release:

CAMBRIDGE, Mass. & NEW ORLEANS–(BUSINESS WIRE)–Harvard University has granted an exclusive license to biotechnology company Obatala Sciences to commercialize innovations that enable the study of human fat tissue in vitro. Harvard Office of Technology Development and Obatala, which manufactures stem cell and hydrogel products to enable next-generation therapeutics discovery, announced the agreement today.

Obatala Sciences operates in the organ-on-a-chip or microphysiological system industry, a fast-growing scientific field that enables pharmaceutical companies to better model human response to therapies, in comparison to traditional laboratory approaches. The licensed Harvard technology, an adipose-on-a-chip, provides a method of obtaining adult-size fat tissue cells for study in vitro and enables the testing of weight loss and cancer-targeting therapeutics without the need for testing in animals. The adipose chips can respond to starvation and simulated meals, and they demonstrate key hormonal activity that is a hallmark of adipose as a functional organ. This ground-breaking technology provides a more accurate and dynamic model of human tissue in its diseased state compared to traditional two-dimensional culture.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?